Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00246688

NCT00246688
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You have been diagnosed with one of the following cancers: epithelial ovarian cancer, peritoneal cavity cancer, or fallopian tube cancer
  • You have had no more than 2 previous chemotherapy treatments, and your most recent chemotherapy included a platinum-based drug
  • Your cancer has gotten worse, or you have developed symptoms of it coming back, either during your last treatment or within 6 months of finishing it
  • It has been at least 4 weeks since your last radiation therapy or chemotherapy
  • It has been at least 3 weeks since your last immunotherapy treatment
  • You have recovered well enough from any previous surgery, radiation, or chemotherapy (hair loss does not count against this)
  • Your doctors expect you to live for at least 3 more months

Who may not be able to join:

  • You have had more than 2 previous chemotherapy treatments
  • You have previously been treated with a type of drug called epothilones
  • You have taken an experimental/investigational drug within the past 4 weeks, or have not fully recovered from its side effects
  • You have previously had radiation treatment covering your entire pelvic area
  • You have cancer that has spread to the brain and is causing symptoms that require whole-brain radiation treatment
  • You currently have an active infection
  • You have or have had another type of cancer, unless it was non-melanoma skin cancer, early-stage cervical cancer (carcinoma in situ), or a cancer that was treated 5 or more years ago with no return
  • You have a type of tumor called a mixed mesodermal tumor
  • You have received hormone therapy for any cancer within the past month
  • You are a woman who could become pregnant (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Bayer
Registry
clinicaltrials_gov
Start date
1 November 2005
Est. completion
1 June 2007

Primary endpoints

Proportion of responders

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov